AIDS

·MeSH: Acquired Immunodeficiency Syndrome

Prevalence

550.1 / 100K

Incidence

26.6 / 100K/yr

19 drugs in development·9 companies·1 clinical trial

Drug Pipeline by Phase

Approved(2)

Drug	Company
mytesi	Jaguar Health, Inc. (JAGX)
syndros	Insys Therapeutics, Inc. (INSY)

Phase 2(2)

Drug	Company
Axicabtagene Ciloleucel	Filana Therapeutics Inc. (FLNA)
Mitomycin	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(2)

Drug	Company
hiv-1 vaccine	MYMETICS CORP (MYMX)
mym-v101	MYMETICS CORP (MYMX)

Preclinical(1)

Drug	Company
rpi-mn	NUTRA PHARMA CORP (NPHC)

Unknown(5)

Drug	Company
Bleomycin Sulfate	ENANTA PHARMACEUTICALS INC (ENTA)
GeneSight	MYRIAD GENETICS INC (MYGN)
ProteinNMore™	BIOADAPTIVES, INC. (BDPT)
SleepEZ™	BIOADAPTIVES, INC. (BDPT)
SleepEZ™ (formerly PrimiSleep™)	BIOADAPTIVES, INC. (BDPT)

Phase 2/Phase 3(7)

BioSniper tracks 19 drugs in development for AIDS across 9 companies.

There are 1 clinical trial targeting AIDS tracked by BioSniper.

The estimated prevalence of AIDS is approximately 550.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.